坦洛新联合托特罗定治疗逼尿肌不稳定前列腺增生

Tamsulosin treatment Tolterodine combined detrusor instability prostatic hyperplasia

目的探讨坦洛新联合托特罗定治疗逼尿肌不稳定前列腺增生的疗效以及药物作用的机制。方法选择我院2009年2月～2010年2月住院治疗的120例逼尿肌不稳定前列腺增生患者，随机分为对照组（坦洛新）及观察组（坦洛新联合托特罗定）各60例，分别于治疗前、治疗后12周进行国际前列腺症状评分（IPSS）、最大尿流率（MFR）及膀胱残余尿量（RUV）测定，并评定其不良反应情况。结果两组患者治疗12周后的IPSS、MFR、RUV均较治疗前明显改善（P〈0．05），且观察组较对照组改善更明显（P〈0．05）。结论坦洛新联合托特罗定治疗逼尿肌不稳定前列腺增生疗效确切，值得推广应用。

Objective To investigate the combined tamsulosin treatment Toherodine treatment of benign prostatic hyperplasia detrusor instability, and the mechanism of drug action. Methods All of 120 cases hospitalized detrusor instability in patients with benign prostatic hyperplasia in our hospital from February 2009-2010 in February were randomly divided into control group （tamsulosin） and the observation group （tamsulosin joint tolterodine） of the 60 cases, respectively, before treatment and 12 weeks after the International Prostate Symptom Score （IPSS）, maximum urinary flow rate （MFR） and the residual urine volume （RUV） determination. Results Two groups of patients after 12 weeks of IPSS, MFR, RUV than before treatment significantly improved （P 〈 0.05）, and the observation group improved more significantly than in the control group （P 〈 0.05）. Conclusion Tamsulosin treatment of detrusor instability combined Toherodine is effective prostatic hyperplasia, should be widely applied.